KYMR Quote, Financials, Valuation and Earnings

Structure Therapeutics, Inc. has a net margin of -3030.7% compared to Kymera Therapeutics, Inc.'s net margin of --. Kymera Therapeutics, Inc.'s return on equity of -30.41% beat Structure Therapeutics, Inc.'s return on equity of -14.89%.

Kymera Therapeutics, Inc. has a consensus price target of $118.00, signalling upside risk potential of 30.97%. On the other hand Structure Therapeutics, Inc. has an analysts' consensus of $108.93 which suggests that it could grow by 73.19%. Given that Structure Therapeutics, Inc. has higher upside potential than Kymera Therapeutics, Inc., analysts believe Structure Therapeutics, Inc. is more attractive than Kymera Therapeutics, Inc..

Kymera Therapeutics, Inc. has a beta of 2.205, which suggesting that the stock is 120.511% more volatile than S&P 500. In comparison Structure Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Kymera Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Structure Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kymera Therapeutics, Inc. pays -- of its earnings as a dividend. Structure Therapeutics, Inc. pays out -- of its earnings as a dividend.

Kymera Therapeutics, Inc. quarterly revenues are $2.9M, which are larger than Structure Therapeutics, Inc. quarterly revenues of --. Kymera Therapeutics, Inc.'s net income of -$87M is lower than Structure Therapeutics, Inc.'s net income of $33.1M. Notably, Kymera Therapeutics, Inc.'s price-to-earnings ratio is -- while Structure Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kymera Therapeutics, Inc. is 194.06x versus -- for Structure Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -3030.7% compared to Kymera Therapeutics, Inc.'s net margin of 21.74%. Kymera Therapeutics, Inc.'s return on equity of -30.41% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Kymera Therapeutics, Inc. has a consensus price target of $118.00, signalling upside risk potential of 30.97%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $870.73 which suggests that it could grow by 10.11%. Given that Kymera Therapeutics, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Kymera Therapeutics, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Kymera Therapeutics, Inc. has a beta of 2.205, which suggesting that the stock is 120.511% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.484%.

Kymera Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.94 per share. Kymera Therapeutics, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Kymera Therapeutics, Inc. quarterly revenues are $2.9M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Kymera Therapeutics, Inc.'s net income of -$87M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Kymera Therapeutics, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 19.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kymera Therapeutics, Inc. is 194.06x versus 5.99x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Revolution Medicines, Inc. has a net margin of -3030.7% compared to Kymera Therapeutics, Inc.'s net margin of --. Kymera Therapeutics, Inc.'s return on equity of -30.41% beat Revolution Medicines, Inc.'s return on equity of -59.94%.

Kymera Therapeutics, Inc. has a consensus price target of $118.00, signalling upside risk potential of 30.97%. On the other hand Revolution Medicines, Inc. has an analysts' consensus of $129.35 which suggests that it could grow by 27.29%. Given that Kymera Therapeutics, Inc. has higher upside potential than Revolution Medicines, Inc., analysts believe Kymera Therapeutics, Inc. is more attractive than Revolution Medicines, Inc..

Kymera Therapeutics, Inc. has a beta of 2.205, which suggesting that the stock is 120.511% more volatile than S&P 500. In comparison Revolution Medicines, Inc. has a beta of 0.991, suggesting its less volatile than the S&P 500 by 0.875%.

Kymera Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revolution Medicines, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kymera Therapeutics, Inc. pays -- of its earnings as a dividend. Revolution Medicines, Inc. pays out -- of its earnings as a dividend.

Kymera Therapeutics, Inc. quarterly revenues are $2.9M, which are larger than Revolution Medicines, Inc. quarterly revenues of --. Kymera Therapeutics, Inc.'s net income of -$87M is higher than Revolution Medicines, Inc.'s net income of -$364.9M. Notably, Kymera Therapeutics, Inc.'s price-to-earnings ratio is -- while Revolution Medicines, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kymera Therapeutics, Inc. is 194.06x versus -- for Revolution Medicines, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sanofi has a net margin of -3030.7% compared to Kymera Therapeutics, Inc.'s net margin of 36.7%. Kymera Therapeutics, Inc.'s return on equity of -30.41% beat Sanofi's return on equity of 12.45%.

Kymera Therapeutics, Inc. has a consensus price target of $118.00, signalling upside risk potential of 30.97%. On the other hand Sanofi has an analysts' consensus of $57.68 which suggests that it could grow by 21.02%. Given that Kymera Therapeutics, Inc. has higher upside potential than Sanofi, analysts believe Kymera Therapeutics, Inc. is more attractive than Sanofi.

Kymera Therapeutics, Inc. has a beta of 2.205, which suggesting that the stock is 120.511% more volatile than S&P 500. In comparison Sanofi has a beta of 0.454, suggesting its less volatile than the S&P 500 by 54.626%.

Kymera Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sanofi offers a yield of 4.61% to investors and pays a quarterly dividend of $2.20 per share. Kymera Therapeutics, Inc. pays -- of its earnings as a dividend. Sanofi pays out 66.53% of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Kymera Therapeutics, Inc. quarterly revenues are $2.9M, which are smaller than Sanofi quarterly revenues of $12.2B. Kymera Therapeutics, Inc.'s net income of -$87M is lower than Sanofi's net income of $4.5B. Notably, Kymera Therapeutics, Inc.'s price-to-earnings ratio is -- while Sanofi's PE ratio is 19.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kymera Therapeutics, Inc. is 194.06x versus 2.36x for Sanofi. Usually stocks with elevated PS ratios are considered overvalued.